Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2021 17:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Host Conference Call for Second Quarter 2021 Financial Results and Corporate Update

NOVATO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and...
July 27, 2021 08:00 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053, an Investigational mRNA-therapy for the Treatment of Glycogen Storage Disease Type III

NOVATO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
July 13, 2021 03:30 ET | Source: Ultragenyx Pharmaceutical Inc.

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Spain

MADRID, Spain, July 13, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and...
July 13, 2021 03:30 ET | Source: Ultragenyx Pharmaceutical Inc.

NOTA DE PRENSA: Ultragenyx anuncia que Mepsevii® (vestronidasa alfa) recibe la aprobación de reembolso para el tratamiento de la mucopolisacaridosis VII en España

MADRID, España, July 13, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., una empresa biofarmacéutica centrada en el desarrollo y comercialización de terapias novedosas para...
June 30, 2021 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

NOVATO, Calif., June 30, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
June 10, 2021 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome

Patient enrollment to begin in early second half of 2021 in U.K. and Canada GeneTx to submit revised protocol to U.S. Food and Drug Administration seeking study resumption in U.S. following May...
June 03, 2021 16:01 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference

NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
May 26, 2021 08:31 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Present at Jefferies Virtual Healthcare Conference

NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
May 19, 2021 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

GeneTx and Ultragenyx Receive Clearance from Health Canada to Begin Clinical Study of GTX-102 in Canada for the Treatment of Angelman Syndrome

SARASOTA, Fla. and NOVATO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of...
May 18, 2021 16:05 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...